vTv Therapeutics Inc. (VTVT)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 6 | 4 | 2 | 0 | 1 | 0 | 37 | 37 |
| Operating profit | $m | -33 | -9 | ||||||
| Net profit | $m | -8 | -13 | -19 | -20 | -18 | -27 | - | -15 |
| EPS reported | $ | -3.20 | -0.38 | ||||||
| Operating cashflow per share | $ | -3.00 | -1.35 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -3.00 | -1.35 | ||||||
| Free cash flow | $m | -25 | -17 | ||||||
| Net debt | $m | -89 | -87 | ||||||
| Book value equity | $m | 64 | 79 | ||||||
| Book value per share | $ | 7.65 | 6.34 | ||||||
| Number of shares | m | 8.42 | 12.41 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 5.23 | 4.28 | ||||||
| P/S LTM | x | 0.00 | 9.14 | ||||||
| P/FCF LTM | x | -13.34 | -20.10 | ||||||
| EV/EBITDA LTM | x | -7.98 | -38.80 | ||||||
| EV/Sales LTM | x | 0.00 | 0.13 | ||||||
| Earnings Yield LTM | % | -8.01% | -1.10% | ||||||
| FCF Yield | % | -7.50% | -4.98% | ||||||
| Quality | |||||||||
| ROE | % | -41.86% | -6.27% | ||||||
| ROIC | % | -39.41% | -11.48% | ||||||
| Operating margin | % | 0.00% | -25.11% | ||||||
| Gross margin | % | 0.00% | +100.00% | ||||||
| FCF/Sales | % | - | -45.50% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -100.00% | +3522.3% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | - | - | ||||||
| Net Debt/EBITDA | x | 2.86 | 13.56 | ||||||
| EBIT/Net interest | x | -5,468.00 | -1,541.83 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -1.38 | -1.10 | ||||||
| Gross debt/equity | x | 0.00 | 0.00 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes. Another key investigational drug is HPP737, an oral phosphodiesterase type 4 (PDE4) inhibitor that does not cross the blood-brain barrier (non-CNS penetrant), designed to treat inflammatory conditions and psoriasis. Beyond these, vTv Therapeutics' broader clinical portfolio includes: TTP273, an oral small-molecule GLP-1 receptor agonist addressing postprandial glucose excursions in cystic fibrosis-related diabetes. HPP3033, which employs a non-electrophilic strategy to activate the Nrf2 pathway for chronic conditions linked to oxidative stress. Azeliragon, a RAGE antagonist being evaluated for inflammatory lung disorders, notably severe COVID-19, alongside pancreatic and breast cancers. HPP971, an Nrf2 activator aimed at renal diseases, developed in collaboration with pharmaceutical partners. Furthermore, vTv holds a licensing agreement with Reneo Pharmaceuticals, Inc. for the development and commercialization of its peroxisome proliferation-activated receptor delta agonist program, which features the compound HPP593. The company has also established various other licensing and research collaborations with entities such as Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S. Established in 2015, vTv Therapeutics is headquartered in High Point, North Carolina, and operates as a subsidiary of MacAndrews & Forbes Incorporated.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes. Another key investigational drug is HPP737, an oral phosphodiesterase type 4 (PDE4) inhibitor that does not cross the blood-brain barrier (non-CNS penetrant), designed to treat inflammatory conditions and psoriasis. Beyond these, vTv Therapeutics' broader clinical portfolio includes: TTP273, an oral small-molecule GLP-1 receptor agonist addressing postprandial glucose excursions in cystic fibrosis-related diabetes. HPP3033, which employs a non-electrophilic strategy to activate the Nrf2 pathway for chronic conditions linked to oxidative stress. Azeliragon, a RAGE antagonist being evaluated for inflammatory lung disorders, notably severe COVID-19, alongside pancreatic and breast cancers. HPP971, an Nrf2 activator aimed at renal diseases, developed in collaboration with pharmaceutical partners. Furthermore, vTv holds a licensing agreement with Reneo Pharmaceuticals, Inc. for the development and commercialization of its peroxisome proliferation-activated receptor delta agonist program, which features the compound HPP593. The company has also established various other licensing and research collaborations with entities such as Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S. Established in 2015, vTv Therapeutics is headquartered in High Point, North Carolina, and operates as a subsidiary of MacAndrews & Forbes Incorporated.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free